<!DOCTYPE html>
<html>
<head>
      <!-- basic -->
      <meta charset="utf-8">
      <meta http-equiv="X-UA-Compatible" content="IE=edge">
      <meta name="viewport" content="width=device-width, initial-scale=1">
      <!-- mobile metas -->
      <meta name="viewport" content="width=device-width, initial-scale=1">
      <meta name="viewport" content="initial-scale=1, maximum-scale=1">
      <!-- site metas -->
      <title> todays'new</title>
      <meta name="keywords" content="">
      <meta name="description" content="">
      <meta name="author" content="">
      <!-- bootstrap css -->
      <link rel="stylesheet" type="text/css" href="css/bootstrap.min.css">
      <!-- style css -->
      <link rel="stylesheet" type="text/css" href="css/style.css">
      <!-- Responsive-->
      <link rel="stylesheet" href="css/responsive.css">
      <!-- fevicon -->
      <link rel="icon" href="images/fevicon.png" type="image/gif" />
      <!-- Scrollbar Custom CSS -->
      <link rel="stylesheet" href="css/jquery.mCustomScrollbar.min.css">
      <!-- Tweaks for older IEs-->
      <link rel="stylesheet" href="https://netdna.bootstrapcdn.com/font-awesome/4.0.3/css/font-awesome.css">
      <!-- fonts -->
      <link href="https://fonts.googleapis.com/css?family=Dancing+Script:400,700|Poppins:400,700&display=swap" rel="stylesheet">
      <!-- owl stylesheets --> 
      <link rel="stylesheet" href="css/owl.carousel.min.css">
      <link rel="stylesheet" href="css/owl.theme.default.min.css">
      <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/fancybox/2.1.5/jquery.fancybox.min.css" media="screen">
      <link href="https://unpkg.com/gijgo@1.9.13/css/gijgo.min.css" rel="stylesheet" type="text/css" />
   </head>
<body>
 <div class="logo-container">
        <img src="/images/vidyagxplogo.jpg" alt="PharmaNews Logo" class="logo">
       </div>
      <div class="header_top_section">
         <div class="container">
            <div class="row">
               <div class="col-sm-12">
                  <div class="header_top_main">
                    
                     <div class="call_text"><a href="#"><span class="padding_right0"><i class="fa fa-phone" aria-hidden="true"></i></span>  Call : +01 1234567890</a></div>
                     <div class="call_text_2"><a href="#"><span class="padding_right0"><i class="fa fa-envelope" aria-hidden="true"></i></span> poornimakarma@gmail.com</a></div>
                     <div class="call_text_1"><a href="#"><span class="padding_right0"><i class="fa fa-map-marker" aria-hidden="true"></i></span> Events</a></div>
                     
                     <div class="call_text_1" ><a href="#"><i class="fa fa-search" aria-hidden="true"></i></a>
                     <input type="text" id="Form_Search" value=""  role="searchbox" class="InputBox "  placeholder="search"  autocomplete="off">
                     <input type="submit" id="Form_Go" class="Button" value="GO">
                   </div>
                </div>
               </div>
           </div>
        </div>  
     </div>
     
     
     
     <h3>
     <div class="col-md-6">
     <p>Nov 22  - Canada's public health agency on Friday confirmed the first case of clade I mpox in Canada, in an person in Manitoba.
        The Public Health Agency of Canada said this travel-related case was associated with an ongoing outbreak of clade I mpox in central and eastern Africa.
        "The individual sought medical care for mpox symptoms in Canada shortly after their return and is currently isolating," the agency said in a statement.</p>
         </div>
         <br>
          <div class="col-md-6">
          <div class="about_img"><img src="images/feed.jpg"></div>
          </div>
          
          <p>BERLIN, Nov 26- A Roche study into using a combination of tiragolumab and tecentriq to treat a form of lung cancer in a phase III trial did not achieve the desired success, the Swiss pharmaceuticals maker said on Tuesday.
            The SKYSCRAPER-01 study "did not reach the primary endpoint of overall survival at the final analysis" in patients with advanced or metastatic non-small cell lung cancer, it said.
             The detailed data will be presented at a medical meeting in 2025, added Roche.</p>
          <div class="col-md-6">
          <div class="about_img" ustify-content: center><img src="images/feed2.jpg"></div>
          <p>Roche continuously reviews its study programmes to determine if any adjustments are necessary for the purposes of ongoing research," it said.
            "Roche will apply the same principles to this programme, with additional data from phase III studies across different settings or tumour types anticipated next year."</p>
          </div>
     </h3>
</body>
</html>